Palatin targets first human studies of obesity drug PL2001 in first half of 2027
PTN•
PTN•Palatin Technologies said it is targeting first-in-human studies of obesity drug PL2001 in the first half of 2027, with initial clinical data expected in the second half. Preclinical studies of its MC4R agonists showed reduced body weight and food intake in obese mice.
Palatin Technologies presented preclinical results at ObesityWeek 2026 showing its MC4R agonists reduced body weight and food intake in obese mice. The company said receptor selectivity findings support the potential to reduce or eliminate hyperpigmentation associated with existing MC4R therapies.
Palatin is targeting first-in-human studies of lead candidate PL2001 in the first half of 2027 and expects initial clinical data in the second half. Long-acting peptides showed extended drug exposure, supporting the potential for once-weekly or less frequent injections compared with currently approved daily therapy.